Department of Ophthamology, Einhorn Clinical Research Center, New York Eye and Ear Infirmary, NY, USA.
J Glaucoma. 2010 Jan;19(1):15-8. doi: 10.1097/IJG.0b013e3181a2fc2d.
To report the midterm clinical outcomes of a surgical technique for inserting the silicone tube of a Baerveldt glaucoma implant into the ciliary sulcus in pseudophakic patients.
Noncomparative, interventional case series in which all glaucoma patients with uncontrolled intraocular pressure (IOP) undergoing Baerveldt glaucoma implant insertion with the silicone tube placed in the ciliary sulcus between 1998 and 2007 were enrolled. Preoperative and postoperative IOP, number of antiglaucoma medications, best-corrected visual acuity, surgical complications, and any subsequent related events or procedures were recorded.
A total of 17 patients (17 eyes) with a mean age of 67.5+/-15.3 (SD) years (range: 39 to 94 y) were included in the study. Mean follow-up was 37.2+/-18.9 months (range: 14 to 72 mo) and mean IOP was reduced from 28.4+/-12.2 (range: 12 to 56 mm Hg) to 12.1+/-5.9 mm Hg (range: 3 to 26 mm Hg) at the last follow-up visit (P<0.001). Eighty-two percent of the cases (14 out of 17) had an IOP between 7 and 18 mm Hg at the end of the follow-up period. The mean number of antiglaucoma medications was reduced from 3.4+/-1.4 (range: 0 to 5) to 2.0+/-1.4 (range: 0 to 4) during the same period (P=0.01). There was no statistically significant difference with respect to mean best-corrected visual acuity (logMAR) at baseline [1.3+/-1 (range: 0.2 to 3)] and at last follow-up visit [1.7+/-1.3 (range: 0.2 to 4); P=0.11]. One patient developed chronic hypotony and another patient had iris incarceration in the tube.
Our findings suggest that placement of a silicone tube into the ciliary sulcus in pseudophakic eyes is an effective alternative for glaucoma management with minor postoperative complications.
报告在非超声乳化白内障摘除术后患者中行 Baerveldt 青光眼引流管植入睫状沟的手术技术的中期临床结果。
本研究为非对照、介入性病例系列研究,共纳入 1998 年至 2007 年间因眼压控制不良而接受 Baerveldt 青光眼引流管植入术且将硅胶管置于睫状沟的所有青光眼患者。记录术前和术后眼压、抗青光眼药物数量、最佳矫正视力、手术并发症以及任何后续相关事件或手术。
共纳入 17 例(17 只眼)患者,平均年龄 67.5+/-15.3(标准差)岁(范围:39 至 94 岁)。平均随访 37.2+/-18.9 个月(范围:14 至 72 个月),末次随访时眼压从 28.4+/-12.2(范围:12 至 56mmHg)降至 12.1+/-5.9mmHg(范围:3 至 26mmHg)(P<0.001)。82%的病例(17 例中有 14 例)在随访期末眼压在 7 至 18mmHg 之间。同期抗青光眼药物的平均数量从 3.4+/-1.4(范围:0 至 5)降至 2.0+/-1.4(范围:0 至 4)(P=0.01)。基线时(logMAR 视力 1.3+/-1,范围:0.2 至 3)和末次随访时(logMAR 视力 1.7+/-1.3,范围:0.2 至 4)最佳矫正视力(BCVA)均值无统计学差异(P=0.11)。1 例患者发生慢性低眼压,另 1 例患者发生虹膜嵌顿于引流管。
我们的研究结果表明,在非超声乳化白内障摘除术后患者中行硅胶管植入睫状沟是一种治疗青光眼的有效方法,术后并发症少。